DEALS
Zhong Lun Law Firm Advised Elpiscience on its Series B Financing of US$100 Million
Zhong Lun Law Firm Advised Elpiscience on its Series B Financing of US$100 Million
On December 28, 2019, Elpiscience announced the completion of its Series B Financing of US$100 million. This round was led by Hyfinity Investment and participated by Tencent, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont, Parkway Global, and others. Current investors, including Lilly Asia Ventures, Hillhouse Capital Group, and CDH Investments, continued to invest in this round of financing.
As the legal counsel of Elpiscience, Zhong Lun Law Firm provided legal services for its Series B Financing, including but not limited to advising on the deal structure, handling negotiation, drafting and revising legal documentation, assisting on the execution of the legal documentation and the closing. Catherine Chen and Shaun Gao are the leading partners of this project. Team members also include Edward Zhou.
Elpiscience is a clinical-stage biopharmaceutical company focusing on cancer immunotherapy. It is committed to leading the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience has a pipeline of more than ten innovative molecules with its most advanced asset, ES101, already in clinical trials. Elpiscience’s innovations cover a wide range of immunology targets (PD-L1, OX40, CD39, CD47, and SIRPα), with a focus on innate immunity and tumor microenvironment.
Professionals
-
-
Catherine F. CHEN
Equity Partner
ShanghaiPractices： Private Equity & Investment Funds,Hong Kong & Overseas Capital Markets,Chinese Mainland Capital MarketsIndustries： Real Estate,Transportation & Logistics,Tourism & Hospitality,Insurance,Telecommunications & Internet,Information & Intelligence Technology,Pharmaceuticals & Life Sciences -
Catherine F. CHEN
Equity Partner
Shanghai
-
